- Home
- SNGX
SNGX
Soligenix Inc.
as 10-14-2025 4:00pm EST
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 10.1M | IPO Year: | 1987 |
| Target Price: | $6.00 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.09 - $6.23 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | -85.78% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soligenix Inc. (SNGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SCHABER CHRISTOPHER J | SNGX | CHAIRMAN, CEO AND PRESIDENT | Oct 2 '25 | Buy | $1.32 | 15,132 | $19,999.96 | 15,511 |
Latest Soligenix Inc. News
SNGX Breaking Stock News: Dive into SNGX Ticker-Specific Updates for Smart Investing
PR Newswire
20 hours ago
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
PR Newswire
8 days ago
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
GlobeNewswire
4 months ago
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
Zacks Small Cap Research
5 months ago
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…
PR Newswire
5 months ago
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Zacks Small Cap Research
6 months ago
Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.
Zacks Small Cap Research
6 months ago
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…
PR Newswire
6 months ago
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Compare SNGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNGX Soligenix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.